$INGN

Inogen Inc (INGN): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Inogen Inc (INGN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ingn-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 INOGEN, INC. AMENDED AND RESTATED 2023 EQUITY INCENTIVE PLAN 1. Purposes of the Plan . The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to prov

Original reporting
Published Jun 11, 2026, 8:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 11, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$INGN
Neutral
medium confidence
Mentioned
$INGN
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$INGNNeutralLow
01

Why it matters

The disclosure updates/clarifies equity compensation framework and governance actions; without new financial targets or business events, it is typically sentiment-neutral.

02

Market read

Primarily administrative governance/compensation information; likely limited immediate trading impact unless specific executive changes are material.

03

What to watch

Traders should check the full 8-K exhibits for specific names, effective dates, and any change-in-control or severance triggers that could affect future cash/equity overhang.

Relevance 6/10Novelty 4/10Timing: Filed after-hours/late day (2026-06-11 16:32 ET)

Background

The article is an SEC EDGAR 8-K for Inogen covering director/officer departure/election and compensatory arrangements, with an exhibit describing the amended and restated 2023 equity incentive plan.

Company-level read

Ticker impact

$INGNNeutralMedium confidence
Context

Inogen filed an 8-K detailing director/officer changes and compensatory arrangements under its equity incentive plan (Item 5.02).

Expected impact

Low likelihood of a sustained price move absent additional disclosed specifics (e.g., severance amounts, new hires with material mandates).

Evidence & confidence

The filing is primarily administrative (plan terms/compensatory arrangements) rather than a new earnings, contract, or regulatory catalyst.

Market effects

Minimal—no sector-wide regulatory, clinical, or product catalyst disclosed.

None indicated.

None indicated.

Counterpoint

If the 8-K includes meaningful executive departures/appointments or unusually structured equity awards, it could signal strategic repositioning not captured in the excerpt.

Key entities

  • Inogen Inc

    Company filing the 8-K with director/officer and compensatory arrangement disclosures.

Related articles

$INGNMedAI 8/10

Inogen (INGN) Cuts Guidance Even As Profitability Climbs

Inogen (NASDAQ:INGN) reported Q2 results with improving profitability and continued international growth, but weakness in the US oxygen rental and direct-to-consumer channels. International revenue was $41.3M (+15% YoY). US sales fell 2% to $42.3M and rental revenue dropped 12% to $11.6M. Full-year 2026 revenue guidance was cut to $355M-$361M.

$INGNMedAI 9/10

Inogen (INGN) Q2 2026 Earnings Call Transcript

Inogen (INGN) reported Q2 2026 revenue of $95.1 million, up 3% year over year, driven by international sales of $41.3 million (+14.8%) and new product contributions. U.S. sales were $42.3 million, down 2.3%. Adjusted EBITDA was $2.4 million (+15.2%). Full-year revenue guidance was cut to $355-$361 million; adjusted EBITDA guidance is about $4 million. Cash was $106.8 million with zero debt.

$INGNMedAI 8/10

Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists

Inogen (INGN) cut its 2026 revenue outlook to $355 million to $361 million from $366 million to $373 million after Q2 results showed ongoing U.S. channel pressure. Q2 U.S. sales fell 2.3% to $42.3M and U.S. rentals fell 11.8% to $11.6M, while international revenue rose 14.8% to $41.3M. Adjusted gross margin rose to 45.6%.

$INGNHigh

Inogen Announces Second Quarter 2026 Financial Results

Inogen Inc (INGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Inogen Announces Second Quarter 2026 Financial Results Reported second quarter revenue of $95.1 million Company raises full-year adjusted EBITDA guidance to approximately $4.0 million BEVERLY, Mass., August 6, 2026 -- Inogen, Inc. (Nasdaq: INGN ), a medical technolog

$SWKSHigh

Skyworks Announces Extension of Expiration Date of Exchange Offers for Qorvo’s Senior Notes due 2029 and 2031

Skyworks Solutions (SWKS) extended its exchange offers for Qorvo's senior notes due 2029 and 2031, with new expiration and withdrawal deadlines set for October 5, 2026. The offers aim to exchange up to $850M of 2029 notes and $700M of 2031 notes. As of September 30, 91.68% of 2029 notes and 93.33% of 2031 notes have been tendered. The offers are contingent on the closing of Skyworks' merger with Qorvo, expected around October 5, 2026.

$OTEXHigh

OpenText Announces Pricing Terms and Results of Cash Tender Offer

OpenText (OTEX) announced the pricing and results of its cash tender offer to purchase up to $300M of its 3.875% Senior Notes due 2028. The offer, which expired on September 30, 2026, will pay a fixed spread over the yield of reference U.S. Treasury Securities. The company plans to use proceeds from a concurrent senior secured notes offering, expected to close on October 1, 2026, to fund the redemption of its 6.900% Senior Secured Notes due 2027 and the tender offer.